公开(公告)号：US20110268808A1

公开(公告)日：2011-11-03

申请号：US13143884

申请日：2010-01-08

申请人： Rajesh Jain ,  Sukhjeet Singh ,  Sanju Dhawan

发明人： Rajesh Jain ,  Sukhjeet Singh ,  Sanju Dhawan

IPC分类号： A61K9/16 ,  A61K31/192 ,  A61K31/397 ,  A61K31/497 ,  A61P9/00 ,  A61P31/04 ,  A61P9/12 ,  A61P9/04 ,  A61P25/00 ,  A61P25/08 ,  A61K31/167 ,  A61P31/12

CPC分类号： A61K9/0095 ,  A61K9/10 ,  A61K9/5026 ,  A61K9/5084 ,  A61K31/00 ,  A61K31/167 ,  A61K31/192 ,  A61K31/43 ,  A61K31/496

摘要： Orally deliverable dual-release pharmaceutical suspensions, having a first portion comprising an immediate release form of the active in the solution form or granules or suspended form in the vehicle/medium preferably in the solution form and a second portion comprising a sustained-release form of active in the form of microgranules/microparticles suspended in the immediate release fraction of the solulabilised active agent which comprise a core and at least one coat suitable for liquid dosage forms for the administration of the active ingredients, wherein the core comprises at least one active agent(s) or its pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; optionally at least one water insoluble, and optionally one or more pharmaceutically acceptable excipient(s); and at least one coat comprising at least one pH independent water-insoluble polymer(s) along with one or more pharmaceutically acceptable excipient(s). This coated microparticles and solution of the active agent in the vehicle ensures a dual release profile i.e. immediate release profile as well as predetermined sustained release profile of the active agent and also ensures maintenance of said release profile over time. The present invention can be administered either in the form of ready to use suspension or in the form of powder ready for reconstitution. Further, this invention provides process of preparation of such suspensions and method of using them.

摘要翻译： 口服递送双释放药物悬浮液，其第一部分包含溶液形式的活性物质的立即释放形式或载体/培养基中的颗粒或悬浮形式，优选溶液形式，第二部分包含缓释形式的缓释形式 活性剂为悬浮于溶解活性剂的速释级分中的微粒/微粒的形式，其包含核心和至少一种适用于施用活性成分的液体剂型的涂层，其中所述核心包含至少一种活性剂 衍生物，异构体，多晶型物，溶剂合物，水合物，类似物，对映异构体，互变异构形式或其混合物; 任选地至少一种水不溶性和任选的一种或多种药学上可接受的赋形剂; 和至少一种包含至少一种与pH无关的水不溶性聚合物以及一种或多种药学上可接受的赋形剂的包衣。 该涂覆的微粒和活性剂在车辆中的溶液确保了双重释放特征，即立即释放特征以及活性剂的预定的持续释放特性，并且还确保随着时间的推移维持所述释放特性。 本发明可以以即用型悬浮液的形式或以准备重新配制的粉末形式施用。 此外，本发明提供了这种悬浮液的制备方法和使用它们的方法。

公开(公告)号：US07371412B2

公开(公告)日：2008-05-13

申请号：US10551797

申请日：2004-12-31

申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Aniruddha Datta

发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Aniruddha Datta

IPC分类号： A61K36/00

CPC分类号： A61K36/47 ,  A61K36/185 ,  A61K36/48 ,  A61K2300/00

摘要： The invention relates to novel compositions comprising of an extract of the plant Euphorbia prostrata, particularly with pharmaceutically acceptable carrier(s)/base(s), optionally with additional therapeutic agent(s) useful for the treatment of anorectal disease and colonic diseases such as hemorrhoids, fissures, cracks, fistulas, abscesses, inflammatory bowel disease, and the like. The novel compositions possess properties to control inflammation, prevent capillary bleeding and fragility in mammalians, particularly human beings. Process for the preparation of such novel compositions comprising an extract of the plant Euphorbia prostrata and pharmaceutically acceptable carrier(s)/base(s) useful for the treatment of anorectal disease including hemorrhoids, and colonic diseases are also provided. The composition comprise of flavonoidal and phenolic constituents extracted from the plant Euphorbia prostrata that possess anti-inflammatory, analgesic, haemostatic and wound-healing properties.

摘要翻译： 本发明涉及包含植物大戟提取物，特别是与药学上可接受的载体/碱的提取物的新型组合物，任选地可用于治疗肛门直肠疾病和结肠疾病的其它治疗剂，例如 痔疮，裂缝，裂缝，瘘，脓肿，炎症性肠病等。 该新型组合物具有控制哺乳动物，特别是人类的炎症，防止毛细血管出血和脆性的性质。 还提供了制备这种新型组合物的方法，该组合物包含植物大戟草提取物和可用于治疗包括痔疮和结肠疾病在内的肛门直肠疾病的药学上可接受的载体/碱基。 该组合物包含从具有抗炎，镇痛，止血和伤口愈合特性的植物大戟科提取的黄酮和酚成分。

公开(公告)号：US20060159748A1

公开(公告)日：2006-07-20

申请号：US11311220

申请日：2005-12-20

申请人： Rajesh Jain ,  Sukhjeet Singh ,  Rohit Kumar ,  Marius De Winter

发明人： Rajesh Jain ,  Sukhjeet Singh ,  Rohit Kumar ,  Marius De Winter

IPC分类号： A61K31/55 ,  A61K9/20

CPC分类号： A61K9/2077 ,  A61K31/55

摘要： The invention is related to an oral immediate release formulation of Benzazepin-1-acetic acid derivatives comprising a) said active substance in an amount of up to 65% of the total weight of the formulation; b) at least 10% w/w an alkaline compound or a mixture of alkaline compounds; c) between 0.1 and 10% of one or more surfactants, and d) optionally comprises auxiliary materials an amount of between 1% and 45% of the total weight of the formulation.

摘要翻译： 本发明涉及苯扎氮平-1-乙酸衍生物的口服立即释放制剂，其包含a）所述活性物质的量高达制剂总重量的65％; b）至少10％w / w的碱性化合物或碱性化合物的混合物; c）0.1至10％的一种或多种表面活性剂，和d）任选地包含占制剂总重量的1％至45％的量的辅助材料。

公开(公告)号：US09642808B2

公开(公告)日：2017-05-09

申请号：US12672180

申请日：2008-08-11

申请人： Rajesh Jain ,  Sukhjeet Singh ,  Sampath Kumar Devarajan

发明人： Rajesh Jain ,  Sukhjeet Singh ,  Sampath Kumar Devarajan

IPC分类号： A61K31/343 ,  A61K9/20 ,  A61K9/28 ,  A61K31/365

CPC分类号： A61K9/2077 ,  A61K9/2013 ,  A61K9/2846 ,  A61K31/365

摘要： Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases).

公开(公告)号：US08551451B2

公开(公告)日：2013-10-08

申请号：US13125708

申请日：2009-10-23

申请人： Rajesh Jain ,  Sukhjeet Singh ,  Lavit Jambu

发明人： Rajesh Jain ,  Sukhjeet Singh ,  Lavit Jambu

IPC分类号： A61K49/00 ,  A61K39/00 ,  A61K39/02

CPC分类号： A61K39/05 ,  A61K39/0018 ,  A61K39/08 ,  A61K39/099 ,  A61K39/102 ,  A61K39/12 ,  A61K39/13 ,  A61K39/292 ,  A61K2039/5252 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N2730/10134 ,  C12N2770/32634 ,  Y02A50/466

摘要： The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by Haemophilus influenzae and polio viruses. The present invention also relates to inclusion of antigens for protection against infections caused Hepatitis virus and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.

摘要翻译： 本发明涉及包含抗原混合物的组合疫苗，用于防止诸如白喉，破伤风，无细胞百日咳和由流感嗜血杆菌和脊髓灰质炎病毒引起的感染。 本发明还涉及包含用于防止引起的肝炎病毒和其他病原体的感染的抗原，使得疫苗的施用可以同时针对多于一种的病原体免疫受试者。 本发明特别涉及包含上述抗原的完全液体稳定的组合疫苗及其制备方法。

公开(公告)号：US20110223249A1

公开(公告)日：2011-09-15

申请号：US12672180

申请日：2008-08-11

申请人： Rajesh Jain ,  Sukhjeet Singh ,  Sampath Kumar Devarajan

发明人： Rajesh Jain ,  Sukhjeet Singh ,  Sampath Kumar Devarajan

IPC分类号： A61K31/343 ,  A61K9/00 ,  A61K9/24 ,  A61K9/28 ,  A61P35/00 ,  A61P11/00 ,  A61P25/00 ,  A61P9/00 ,  A61P29/00 ,  A61P31/00

CPC分类号： A61K9/2077 ,  A61K9/2013 ,  A61K9/2846 ,  A61K31/365

摘要： Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases).

摘要翻译： 包含霉酚酸钠作为活性剂的延长释放药物组合物，其中当进行体外溶出研究时，所述组合物表现出特征性释放曲线，并且其中所述霉酚酸钠以持续的方式在体内以这种方式长时间释放 提供了大大减轻或至少降低引起任何相关胃肠道副作用而不损害所述活性剂的生物利用度的机会的量。 本发明还提供了使用这种剂型的剂型组合物和预防和/或治疗方法的制备方法。 本发明的组合物可用于治疗，例如预防，改善和/或治疗指示的疾病/病症，特别是用于治疗或预防器官，组织或细胞同种异体移植物或异种移植物排斥反应的免疫抑制剂，例如， 移植后，或免疫介导的疾病（自身免疫性疾病）的管理。

公开(公告)号：US20100204333A1

公开(公告)日：2010-08-12

申请号：US11988860

申请日：2006-07-19

申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Munish Talwar

发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Munish Talwar

IPC分类号： A61K31/18 ,  A61P25/00 ,  A61P25/06

CPC分类号： A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/209 ,  A61K9/4808 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/5084 ,  A61K31/18 ,  A61K31/192 ,  A61K31/415

摘要： Pharmaceutical modified release dosage form comprising at least one cyclooxygenase enzyme inhibitor or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof as active agent, with a pharmaceutically acceptable carrier for controlling the release of the cyclooxygenase enzyme inhibitor is provided. The dosage form preferably provides a release of not more than about 60% of the cyclooxygenase enzyme inhibitor in 1 hour and not less than about 75% of the cyclooxygenase enzyme inhibitor after 12 hours when tested in accordance with the dissolution method (I) described herein employing Distilled water with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (II) described herein employing pH 7.0 Phosphate buffer with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (III) described herein employing 0.001 N Hydrochloric acid with 1.0% Sodium lauryl sulphate as dissolution medium. Further, the pharmaceutical composition of the present invention when tested in a group of healthy humans preferably achieves a mean peak plasma concentration (Cmax) after at least about 1 hour of administration of the dosage form. The present invention also provides process of preparing such dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form.

摘要翻译： 提供了包含至少一种环加氧酶酶抑制剂或其药学上可接受的盐，酯，前药，溶剂化物或其衍生物作为活性剂的药物改性释放剂型，以及用于控制环加氧酶抑制剂释放的药学上可接受的载体。 根据本文所述的溶解方法（I）测试时，剂型优选在12小时后提供不超过约60％的环氧合酶抑制剂的释放量，并且不少于约75％的环氧合酶抑制剂。 使用2.0％十二烷基硫酸钠作为溶解介质的蒸馏水或根据本文所述的溶解方法（II），使用pH 7.0的磷酸盐缓冲液，含有2.0％十二烷基硫酸钠作为溶解介质，或根据溶解方法（III） 本文使用0.001N盐酸与1.0％十二烷基硫酸钠作为溶解介质。 此外，当在一组健康人中测试时，本发明的药物组合物优选在施用剂型至少约1小时后达到平均峰值血浆浓度（C max）。 本发明还提供了制备这种剂型组合物的方法和使用这种剂型的预防和/或治疗方法。

公开(公告)号：US20110206726A1

公开(公告)日：2011-08-25

申请号：US13125708

申请日：2009-10-23

申请人： Rajesh Jain ,  Sukhjeet Singh ,  Lavit Jambu

发明人： Rajesh Jain ,  Sukhjeet Singh ,  Lavit Jambu

IPC分类号： A61K39/385 ,  A61K39/295 ,  A61P37/04 ,  A61P31/04 ,  A61P31/14 ,  A61P31/12 ,  A61P31/20

CPC分类号： A61K39/05 ,  A61K39/0018 ,  A61K39/08 ,  A61K39/099 ,  A61K39/102 ,  A61K39/12 ,  A61K39/13 ,  A61K39/292 ,  A61K2039/5252 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N2730/10134 ,  C12N2770/32634 ,  Y02A50/466

摘要： The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by Haemophilus influenzae and polio viruses. The present invention also relates to inclusion of antigens for protection against infections caused Hepatitis virus and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.

摘要翻译： 本发明涉及包含抗原混合物的组合疫苗，用于防止诸如白喉，破伤风，无细胞百日咳和由流感嗜血杆菌和脊髓灰质炎病毒引起的感染。 本发明还涉及包含用于防止引起的肝炎病毒和其他病原体的感染的抗原，使得疫苗的施用可以同时针对多于一种的病原体免疫受试者。 本发明特别涉及包含上述抗原的完全液体稳定的组合疫苗及其制备方法。

公开(公告)号：US20110195087A1

公开(公告)日：2011-08-11

申请号：US13125679

申请日：2009-10-23

申请人： Rajesh Jain ,  Sukhjeet Singh ,  Lavit Jambu

发明人： Rajesh Jain ,  Sukhjeet Singh ,  Lavit Jambu

IPC分类号： A61K39/116 ,  A61P37/04 ,  A61P31/04

CPC分类号： A61K39/0018 ,  A61K39/05 ,  A61K39/08 ,  A61K39/099 ,  A61K39/102 ,  A61K39/12 ,  A61K39/13 ,  A61K39/292 ,  A61K2039/5252 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N2730/10134 ,  C12N2770/32634 ,  Y02A50/466

摘要： The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, whole cell pertussis and polio. The present invention also relates to inclusion of one or more antigens in the said combination vaccine, for protection against infections caused by Haemophilus influenzae. Hepatitis virus, and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.

摘要翻译： 本发明涉及包含用于保护白血病，破伤风，全细胞百日咳和脊髓灰质炎等疾病的抗原混合物的组合疫苗。 本发明还涉及在所述组合疫苗中包含一种或多种抗原，以防止流感嗜血杆菌引起的感染。 肝炎病毒和其他病原体，使得疫苗的施用可以同时针对多于一种的病原体免疫受试者。 本发明特别涉及包含上述抗原的完全液体稳定的组合疫苗及其制备方法。

公开(公告)号：US20080247962A1

公开(公告)日：2008-10-09

申请号：US10586545

申请日：2005-01-19

申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh

发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh

IPC分类号： A61K9/12 ,  A61K31/045 ,  A61K31/40 ,  A61P3/00 ,  A61K31/351

CPC分类号： A61K31/366 ,  A61K31/045 ,  A61K31/40 ,  A61K45/06 ,  A61K2300/00

摘要： A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from (24) to (39) carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and HMG CoA reductase inhibitor, its salts, analogs or derivatives thereof, preferably statins, optionally with pharmaceutically acceptable excipients, and process of preparation of such composition is provided. Also provided are method of treatment and use of such composition for reducing abnormal lipid parameters associated with hyperlipidemia.

摘要翻译： 一种新型药物组合物，其包含来自（24）至（39）个碳原子的较高级脂族醇的混合物; 选自树脂和颜料，烃，酯，酮和醛中的至少一种组分和酚类化合物，和HMG CoA还原酶抑制剂，其盐，类似物或衍生物，优选他汀类，任选地具有药学上可接受的赋形剂，以及制备方法 提供了这种组合物。 还提供了治疗和使用这种组合物以减少与高脂血症相关的异常脂质参数的方法。